Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Generative artificial intelligence for small molecule drug design.
Kanakala GC, Devata S, Chatterjee P, Priyakumar UD. Kanakala GC, et al. Among authors: devata s. Curr Opin Biotechnol. 2024 Oct;89:103175. doi: 10.1016/j.copbio.2024.103175. Epub 2024 Aug 5. Curr Opin Biotechnol. 2024. PMID: 39106790 Review.
Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.
D'Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccosanti C, David K, Risch Z, Murga-Zamalloa C, Devata S, Wilcox R, Savani M, Courville EL, Bachanova V, Rabinovich E, Peace D, Osman F, Epperla N, Kenkre VP. D'Angelo CR, et al. Among authors: devata s. Hematol Oncol. 2021 Oct;39(4):473-482. doi: 10.1002/hon.2902. Epub 2021 Aug 4. Hematol Oncol. 2021. PMID: 34347909 Free PMC article.
Clinical application of next generation sequencing in lymphoma.
Scott AJ, Tokaz MC, Shango M, Devata S, Carty SA, Kaminski MS, Chinnaiyan AM, Phillips TJ, Wilcox RA. Scott AJ, et al. Among authors: devata s. Leuk Lymphoma. 2021 Apr;62(4):868-873. doi: 10.1080/10428194.2020.1846734. Epub 2020 Nov 16. Leuk Lymphoma. 2021. PMID: 33191827
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Huen A, et al. Among authors: devata s. Cancers (Basel). 2020 Aug 15;12(8):2293. doi: 10.3390/cancers12082293. Cancers (Basel). 2020. PMID: 32824175 Free PMC article.
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM. Bartlett NL, et al. Among authors: devata s. Blood. 2020 Nov 19;136(21):2401-2409. doi: 10.1182/blood.2019004701. Blood. 2020. PMID: 32730586 Free PMC article. Clinical Trial.
34 results